Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 801–900 of 1,018
Obesity, Hypertension, and Insulin Resistance
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2088 · Cited by 87
Galzerano, D., TAMMARO, P., DELVISCOVO, L., Lama, D., Galzerano, A., BREGLIO, R., Tuccillo, B., Paolisso, G., & Capogrosso, P. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.06.011 · Cited by 82
Okin, P. M., Hille, D. A., Larstorp, A. C. K., Wachtell, K., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05728 · Cited by 81
Self-citationPrinciples of Screening for Chronic Kidney Disease
Jaar, B. G., Khatib, R., Plantinga, L., Boulware, L. E., & Powe, N. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02540607 · Cited by 81
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Hall, F. C., & Dalbeth, N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei012 · Cited by 81
Collaborative, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00804-7 · Cited by 81
Brown, N. J., Kumar, S., Painter, C. A., & Vaughan, D. E. (2002) · Hypertension · doi:10.1161/01.hyp.0000040264.15961.48 · Cited by 81
Wang, F., Lu, X., Liu, M., Feng, Y., Zhou, S.-F., & Yang, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0514-1 · Cited by 81
Liu, J., Gu, C. Y., Cabigas, E. B., Pendergrass, K. D., Brown, M. E., Luo, Y., & Davis, M. E. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.008 · Cited by 81
Management of hypertension in the elderly
Pimenta, E., & Oparil, S. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.27 · Cited by 81
Self-citationCardiorenal Syndrome Type 4: A Review
Clementi, A., Virzì, G. M., Goh, C. Y., Cruz, D. N., Granata, A. R. M., Vescovo, G., & Ronco, C. (2013) · Cardiorenal Medicine · doi:10.1159/000350397 · Cited by 81
Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study
Castillo, J., Álvarez‐Sabín, J., Martínez‐Vila, E., Montaner, J., Sobrino, T., Vivancos, J., & on behalf of the MÍTICO Study Investigators* (2009) · Journal of Neurology · doi:10.1007/s00415-009-0058-4 · Cited by 81
Nakayama, S., Watada, H., Mita, T., Ikeda, F., Shimizu, T., Uchino, H., Fujitani, Y., Hirose, T., & Kawamori, R. (2008) · Hypertension Research · doi:10.1291/hypres.31.7 · Cited by 81
De Luca, N., Izzo, R., Iaccarino, G., Malini, P. L., Morisco, C., Rozza, F., Iovino, G. L., Rao, M. A. E., Bodenizza, C., Lanni, F., et al. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000173526.65555.55 · Cited by 80
Lowering blood pressure for cardiovascular risk reduction
McInnes, G. T. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000165622.34192.fd · Cited by 80
Dong, Y., Liu, L., Kataoka, K., Nakamura, T., Fukuda, M., Tokutomi, Y., Nako, H., Ogawa, H., & Kim‐Mitsuyama, S. (2009) · Diabetologia · doi:10.1007/s00125-009-1575-5 · Cited by 80
Mitchell, G. F. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0037-1 · Cited by 80
Collecting duct (pro)renin receptor targets ENaC to mediate angiotensin II-induced hypertension
Peng, K., Lu, X., Wang, F., Nau, A., Chen, R., Zhou, S.-F., & Yang, T. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00178.2016 · Cited by 80
Optimal Medical Management of Asymptomatic Carotid Stenosis
Hackam, D. G. (2021) · Stroke · doi:10.1161/strokeaha.120.033994 · Cited by 80
Journal of Experimental and Clinical Medicine
(2021) · Journal of Experimental and Clinical Medicine · doi:10.5835/jecm · Cited by 80
Meems, L. M. G., Cannon, M. V., Mahmud, H., Voors, A. A., van Gilst, W. H., Silljé, H. H. W., Ruifrok, W.-P. T., & de Boer, R. A. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.06.004 · Cited by 79
Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2013) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.112.977777 · Cited by 79
Self-citationObesity and Chronic Kidney Disease
Kramer, H. (2006) · KARGER eBooks · doi:10.1159/000095315 · Cited by 79
Cardiovascular Disease in the Elderly
Schwartz, J. B., & Zipes, D. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00080-9 · Cited by 79
Neutel, J. M., Saunders, E., Bakris, G. L., Cushman, W. C., Ferdinand, K. C., Ofili, E., Sowers, J. R., Weber, M. A., & on behalf of the INCLUSIVE Investigators (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.04720.x · Cited by 79
Cardiac remodeling in systemic hypertension
Kenchaiah, S., & Pfeffer, M. A. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00168-8 · Cited by 80
Astor, B. C., Arnett, D. K., Brown, A., & Coresh, J. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.12.047 · Cited by 79
Neilan, T. G., Mongeon, F., Shah, R. V., Coelho‐Filho, O. R., Abbasi, S. A., Dodson, J. A., McMullan, C. J., Heydari, B., Michaud, G. F., John, R. M., et al. (2013) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2013.08.013 · Cited by 78
Exploring the dialogism of academic discourse: Heteroglossic Engagement in medical research articles
Fryer, D. L. (2013) · BRILL eBooks · doi:10.1163/9789401209403_011 · Cited by 78
Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Durante, A., Peretto, G., Laricchia, A., Ancona, F., Spartera, M., Mangieri, A., & Cianflone, D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436467 · Cited by 78
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
Mohan, M., Dihoum, A., Mordi, I. R., Choy, A. M., Rena, G., & Lang, C. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.746382 · Cited by 78
Messerli, F. H., Beevers, D. G., Franklin, S. S., & Pickering, T. G. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01017-3 · Cited by 77
Coletta, A. P., Thackray, S. D. R., Nikitin, N. P., & Cleland, J. G. F. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00040-5 · Cited by 76
The Evidence-Based Use of Thiazide Diuretics in Hypertension and Nephrolithiasis
Reilly, R. F., Peixoto, A. J., & Désir, G. V. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04670510 · Cited by 76
Bavishi, C., Bangalore, S., & Messerli, F. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.10.002 · Cited by 76
Haffner, S. M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.008 · Cited by 76
Joseph, G., Marott, J. L., Torp-Pedersen, C. T., Biering‐Sørensen, T., Nielsen, G. N., Christensen, A.-E., Johansen, M. B., Schnohr, P., Søgaard, P., & Møgelvang, R. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13786 · Cited by 76
Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?
Lüscher, T. F., & Mahfoud, F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu195 · Cited by 76
Lin, A., Lowe, A., Sidhu, K., Harrison, W., Ruygrok, P., & Stewart, R. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283567b94 · Cited by 76
Regression of Left Ventricular Hypertrophy and Prevention of Stroke in Hypertensive Subjects
Verdecchia, P., Angeli, F., Gattobigio, R., Sardone, M., Pede, S., & Reboldi, G. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.10.018 · Cited by 76
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
Blood pressure as an example of a biomarker that functions as a surrogate
Desai, M. G., Stockbridge, N., & Temple, R. (2006) · The AAPS Journal · doi:10.1208/aapsj080117 · Cited by 75
Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice
Vinh, A., Widdop, R. E., Drummond, G. R., & Gaspari, T. A. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm021 · Cited by 76
Zhou, F., Geng, Y., Xin, F., Li, J., Feng, P., Liu, C., Zhao, W., Feng, T., Guastella, A. J., Ebstein, R. P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.007 · Cited by 75
Sparks, M. A., Stegbauer, J., Chen, D., Gomez, J. A., Griffiths, R. C., Azad, H., Herrera, M., Gurley, S. B., & Coffman, T. M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080816 · Cited by 75
Cardiovascular Risk Assessment in Hypertensive Patients
Wang, M. C., & Lloyd‐Jones, D. M. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab021 · Cited by 75
Fifty Years of Thiazide Diuretic Therapy for Hypertension
Moser, M., & Feig, P. U. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.342 · Cited by 75
Watanabe, S., Tagawa, T., Yamakawa, K., Shimabukuro, M., & Ueda, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000187465.55507.85 · Cited by 75
Regenhardt, R. W., Mecca, A. P., Desland, F. A., Ritucci‐Chinni, P. F., Ludin, J. A., Greenstein, D., Bañuelos, C., Bizon, J. L., Reinhard, M. K., & Sumners, C. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.075242 · Cited by 75
Insulin resistance, diabetes and cardiovascular risk: approaches to treatment
Rosenberg, D. E., Jabbour, S. A., & Goldstein, B. J. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00446.x · Cited by 75
Malacco, E., Santonastaso, M., Varì, N. A., Gargiulo, A., Spagnuolo, V., Bertocchi, F., Palatini, P., & PREVAIL Study Investigators (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90129-4 · Cited by 75
Okin, P. M., Hille, D. A., Kjeldsen, S. E., & Devereux, R. B. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007564 · Cited by 75
Self-citationTong, P. C. Y., Kong, A. P. S., So, W., Ng, M. H. L., Yang, X., Ng, M. C. Y., Ronald, C. W., Ho, C. S., Lam, C. W. K., Chow, C., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0887 · Cited by 74
Making Sense of Composite Endpoints in Clinical Research
Baracaldo-Santamaría, D., Feliciano-Alfonso, J. E., Grueso, R. R., Rojas-Rodríguez, L. C., Domínguez-Domínguez, C. A., & Calderón‐Ospina, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134371 · Cited by 74
Chan, K. E., Ikizler, T. A., Gamboa, J. L., Yu, C., Hakim, R. M., & Brown, N. J. (2011) · Kidney International · doi:10.1038/ki.2011.228 · Cited by 74
Yin, T., Maekawa, K., Kamide, K., Saito, Y., Hanada, H., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., et al. (2008) · Hypertension Research · doi:10.1291/hypres.31.1549 · Cited by 74
Medicinal Materials as Eco-friendly Corrosion Inhibitors for Industrial Applications: A Review
El-Shamy, A. M., & Mouneir, S. M. (2022) · Journal of Bio- and Tribo-Corrosion · doi:10.1007/s40735-022-00714-9 · Cited by 74
Aune, D., ó Hartaigh, B., & Vatten, L. J. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.02.008 · Cited by 73
Epidemiology of Resistant Hypertension
Sarafidis, P. A. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00445.x · Cited by 73
The Pleiotropic Effects of Angiotensin Receptor Blockers
Chrysant, S. G., & Chrysant, G. S. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05264.x · Cited by 73
Stears, A. J., Woods, S. H., Watts, M. M., Burton, T. J., Graggaber, J., Mir, F. A., & Brown, M. J. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.189381 · Cited by 73
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman, T. J., Baranowski, B. J., Ashen, M. D., Henrikson, C. A., McAllister, M. W., Braunstein, J. B., & Blumenthal, R. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1490 · Cited by 73
Matsumoto, S., Shimabukuro, M., Fukuda, D., Soeki, T., Yamakawa, K., Masuzaki, H., & Sata, M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-30 · Cited by 74
Bestermann, W. H., Houston, M. C., Hawkins, R. G., Basile, J., Egan, B. M., Lackland, D., Ferrario, C. M., Moore, M. A., Reed, J. W., Rogers, P., et al. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200506000-00009 · Cited by 73
Munger, M. A. (2011) · PubMed Central · Cited by 74
Cardiovascular Therapies and Risk for Development of Diabetes
Pepine, C. J., & Cooper‐DeHoff, R. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.071 · Cited by 73
The hematopoietic system: a new niche for the renin–angiotensin system
Hübert, C., Savary, K., Gasc, J., & Corvol, P. L. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0449 · Cited by 73
Ohshima, K., Mogi, M., Jing, F., Iwanami, J., Tsukuda, K., Min, L., Ogimoto, A., Dahlöf, B., Steckelings, U. M., Unger, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048387 · Cited by 72
Self-citationAT1 Receptor Antagonism Is Proangiogenic in the Brain: BDNF a Novel Mediator
Alhusban, A., Kozak, A., Ergul, A., & Fagan, S. C. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197483 · Cited by 72
Fyhrquist, F., Silventoinen, K., Saijonmaa, O., KONTULA, K. K., Devereux, R. B., Fairé, U. D., Os, I., & Dahlöf, B. (2011) · Journal of Human Hypertension · doi:10.1038/jhh.2011.57 · Cited by 72
Self-citationNakamura, T., Hirota, T., Mizushima, K., Ohki, K., Naito, Y., Yamamoto, N., & Yoshikawa, T. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2541 · Cited by 72
Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
Burnier, M. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700602 · Cited by 72
Neprilysin Inhibitors and Bradykinin
Campbell, D. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00257 · Cited by 72
Nebivolol in the treatment of arterial hypertension
Olawi, N., Krüger, M., Grimm, D. G., Infanger, M., & Wehland, M. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13248 · Cited by 72
Chrysant, S. G. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.06602.x · Cited by 72
Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity
Brewster, L. M., van Montfrans, G. A., Oehlers, G. P., & Seedat, Y. K. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1422-x · Cited by 71
“Systolic and diastolic dysfunction” in heart failure? Time for a new paradigm
Konstam, M. A. (2003) · Journal of Cardiac Failure · doi:10.1054/jcaf.2003.9 · Cited by 71
Schelbert, E. B., Sabbah, H. N., Butler, J., & Gheorghiade, M. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005619 · Cited by 71
The renin–angiotensin system, bone marrow and progenitor cells
Durik, M., Pessôa, B. S., & Roks, A. J. M. (2012) · Clinical Science · doi:10.1042/cs20110660 · Cited by 71
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076262 · Cited by 71
Self-citationBramante, C. T., Beckman, K. B., Mehta, T., Karger, A. B., Odde, D. J., Tignanelli, C. J., Buse, J. B., Johnson, D. M., Watson, R. H. B., Daniel, J. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae159 · Cited by 71
Leung, P. S., & Carlsson, P. (2005) · Pancreas · doi:10.1097/01.mpa.0000158028.76666.76 · Cited by 71
Efficacy and Tolerability of Nebivolol Compared with Other Antihypertensive Drugs: A Meta-Analysis
Bortel, L. M. V., Fıcı, F., & Mascagni, F. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808010-00005 · Cited by 71
David, S., Kümpers, P., Lukasz, A. H., Kielstein, J. T., Haller, H. G., & Fliser, D. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832be575 · Cited by 71
The frail renin–angiotensin system
Abadir, P. M. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.08.004 · Cited by 70
Impact of the renin-angiotensin system on lipid and carbohydrate metabolism
Strazzullo, P., & Galletti, F. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200405000-00010 · Cited by 70
Trask, A. J., Groban, L., Westwood, B. M., Varagić, J., Ganten, D., Gallagher, P. E., Chappell, M. C., & Ferrario, C. M. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.51 · Cited by 70
Hypertension, left ventricular hypertrophy, and sudden death
Tin, L., Beevers, D. G., & Lip, G. Y. H. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0105-6 · Cited by 70
Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage
Horiuchi, M., & Mogi, M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01167.x · Cited by 70
Hypertension and the Cardiometabolic Syndrome
Manrique, C. M., Lastra, G., Whaley‐Connell, A. T., & Sowers, J. R. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04617.x · Cited by 70
Xue, H., Lu, Z., Tang, W. L., Pang, L. W., Wang, G. M., Wong, G. W., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008170.pub2 · Cited by 70
Okin, P. M., Oikarinen, L., Viitasalo, M., Toivonen, L., Kjeldsen, S. E., Nieminen, M. S., Edelman, J. M., Dahlöf, B., & Devereux, R. B. (2009) · Circulation · doi:10.1161/circulationaha.108.812313 · Cited by 70
Self-citationImpact of lower achieved blood pressure on outcomes in hypertensive patients
Okin, P. M., Hille, D. A., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283516499 · Cited by 70
Self-citationInteractions Between the Immune and the Renin–Angiotensin Systems in Hypertension
Rudemiller, N. P., & Crowley, S. D. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.06591 · Cited by 70
Fortuño, A., Bidegain, J., Robador, P. A., Hermida, J., López‐Sagaseta, J., Beloqui, Ó., Díez, J., & Zalba, G. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.129353 · Cited by 70
Obesidade visceral, hipertensão arterial e risco cárdio-renal: uma revisão
Rosa, E. C., Zanella, M. T., Ribeiro, A. B., & Kohlmann, O. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000200005 · Cited by 70
Sharrief, A. Z., & Grotta, J. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00021-2 · Cited by 71
Konishi, A., & Berk, B. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304913200 · Cited by 70
Schwammenthal, Y., & Tanné, D. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00826-9 · Cited by 70
Racial differences in the outcomes of patients with diastolic heart failure
East, M. A., Peterson, E. D., Shaw, L. K., Gattis, W. A., & O’Connor, C. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.017 · Cited by 71
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.